| Neos Therapeutics is a pharmaceutical company. Co.'s approved U.S. Food and Drug Administration (FDA) attention deficit hyperactivity disorder (ADHD) products are: Adzenys extended-release (XR)-orally disintegrating tablet (ODT) (amphetamine) for the treatment of ADHD in patients six years and older; Cotempla XR-ODT (methylphenidate) for the treatment of ADHD in patients six to 17 years old; and Adzenys ER (amphetamine) oral suspension for the treatment of ADHD in patients six years and older. Co.'s clinical-stage asset, NT0502 (N-desethyloxybutynin), is an active metabolite of the active ingredient in DITROPAN® (oxybutynin chloride), an FDA-approved medication for a urological condition. We show 24 historical shares outstanding datapoints in our coverage of NEOS's shares outstanding history.|
Understanding the changing numbers of NEOS shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like NEOS versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching NEOS by allowing them to research NEOS shares outstanding history
as well as any other stock in our coverage universe.